Format

Send to

Choose Destination
Pharmacogenomics. 2014;15(15):1903-30. doi: 10.2217/pgs.14.147.

Pharmacogenomics of antimicrobial agents.

Author information

1
Department of General Medicine & Infectious Diseases, The Alfred Hospital, Melbourne, Victoria, Australia.

Abstract

Antimicrobial efficacy and toxicity varies between individuals owing to multiple factors. Genetic variants that affect drug-metabolizing enzymes may influence antimicrobial pharmacokinetics and pharmacodynamics, thereby determining efficacy and/or toxicity. In addition, many severe immune-mediated reactions have been associated with HLA class I and class II genes. In the last two decades, understanding of pharmacogenomic factors that influence antimicrobial efficacy and toxicity has rapidly evolved, leading to translational success such as the routine use of HLA-B*57:01 screening to prevent abacavir hypersensitivity reactions. This article examines recent advances in the field of antimicrobial pharmacogenomics that potentially affect treatment efficacy and toxicity, and challenges that exist between pharmacogenomic discovery and translation into clinical use.

KEYWORDS:

antibacterials; antifungals; antimalarials; antivirals; pharmacogenomics

PMID:
25495412
PMCID:
PMC4296903
DOI:
10.2217/pgs.14.147
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center